AstraZeneca’s R&D credentials face scrutiny after surprise late-stage trial setback
AstraZeneca’s long-running record of clinical success and strong share performance under CEO Pascal Soriot has been challenged by the unexpected Phase III failure of Wainua in a cardiac indication. The setback eliminated about $20 billion of market value and has redirected investor attention to two major late-stage oncology trials, SERENA-4 and AVA…